Mainz Biomed

MYNZPre-clinical

Mainz Biomed is a commercial-stage biotech company dedicated to revolutionizing cancer screening through advanced molecular diagnostics. Its core product, ColoAlert®, is a CE-marked and FDA-registered stool DNA test for the detection of colorectal cancer and advanced adenomas. The company is actively pursuing a pivotal FDA clinical study (ReconAAsense) to gain U.S. market approval and is developing a portfolio of next-generation tests, including PancAlert for pancreatic cancer and a multi-cancer early detection (MCED) panel. Its strategy leverages a proprietary PCR-based platform to deliver accurate, accessible, and non-invasive screening solutions.

Market Cap

$6.3M

Employees

50-100

Focus

Biotech

MYNZ · Stock Price

USD 0.50581.90 (-99.91%)

Historical price data

AI Company Overview

Technology Platform

Proprietary PCR-based platform for detecting DNA methylation biomarkers in stool samples, enabling non-invasive, at-home screening for colorectal and other gastrointestinal cancers.

Funding History

Total raised: $23.5M

PIPE$8.5MUndisclosedMar 15, 2023

IPO$15MUndisclosedNov 15, 2021

Opportunities

The primary growth opportunity is U.S.

FDA approval and commercialization of ColoAlert®, targeting the multi-billion dollar CRC screening market.

Further opportunities lie in expanding the product portfolio to other lethal cancers like pancreatic cancer (PancAlert) and developing a multi-cancer detection panel, leveraging the same scalable platform technology.

Risk Factors

Key risks include the failure of the pivotal ReconAAsense trial to meet endpoints, preventing U.S.

market entry; the need for substantial additional funding leading to shareholder dilution; and intense competition in the CRC screening market from established players like Exact Sciences' Cologuard.

Competitive Landscape

Mainz Biomed's main competitor in colorectal cancer screening is Exact Sciences with Cologuard. It differentiates ColoAlert® by focusing on high sensitivity for pre-cancerous adenomas, a user-friendly design, and a qPCR-based platform for potential cost and scalability advantages. In the emerging multi-cancer detection space, it faces competition from blood-based test developers like Grail.